So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs. The Foster City, ...

with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products. The litigation extends back to 2018, when ViiV – a joint venture majority ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

As the U.S. market grapples with the impact of newly imposed tariffs and a broad-based sell-off, investors are keenly ...

Gilead Sciences has announced the European Medicines ... The EMA's Committee for Medicinal Products for Human Use (CHMP) will review the MAA under the centralised licensing procedure for all ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... Based on the assessment of EMA’s Committee for Medicinal Products for Human Use (CHMP) that twice-yearly lenacapavir for prevention is ...